Bachem Holding AG (BANB) AI Stock Analysis

• Market Cap: CHF3.96B
• Dividend Yield: 1.52%
• Average Volume (3M): 136.12K
• Price to Earnings (P/E): 33.0
• Beta (1Y): 1.28
• Revenue Growth: 4.84%
• EPS Growth: 7.45%
• Country: CH
• Employees: 2,207
• Sector: Healthcare
• Sector Strength: 39
• Industry: Chemicals
• EPS (TTM): 1.60
• Shares Outstanding: 75,000,000
• 10 Day Avg. Volume: 109,874
• 30 Day Avg. Volume: 136,119
• PEG Ratio: 27.92
• Price to Book (P/B): 3.06
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -84.35
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF67.40
• Price Target Upside: 27.05% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

Bachem Holding AG has strong financial performance with robust growth and profitability, contributing significantly to its overall score. Technical indicators are mixed, suggesting moderate momentum without strong trends. Valuation metrics indicate potential overvaluation, which slightly detracts from the score. Despite these concerns, the company's strategic growth investments and stable financial health present a balanced outlook.

Bachem Holding AG Business Overview & Revenue Model

Company Description

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.

How the Company Makes Money

Bachem Holding AG generates revenue primarily through the production and sale of peptides and oligonucleotides, which are essential components in pharmaceutical research and development. The company's key revenue streams include custom synthesis services, where they manufacture these molecules according to client specifications, and catalog products, which are standard offerings for research and development purposes. Bachem collaborates with pharmaceutical companies, biotech firms, and academic institutions, leveraging its advanced production capabilities to support drug development pipelines. Additionally, strategic partnerships and long-term supply agreements with major pharmaceutical companies contribute significantly to its revenue, ensuring a stable and recurring income stream.

Bachem Holding AG Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
577.77M	605.26M	577.32M	531.74M	503.23M	402.00M
	Gross Profit
179.36M	182.56M	176.96M	171.28M	166.73M	128.91M
	EBIT
129.55M	133.05M	129.38M	126.31M	128.04M	95.80M
	EBITDA
166.23M	178.52M	163.28M	157.08M	156.47M	121.72M
	Net Income Common Stockholders
113.57M	120.25M	111.86M	100.68M	114.68M	78.06M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
21.43M	95.20M	298.53M	268.43M	442.36M	23.50M
	Total Assets
647.14M	1.92B	1.68B	1.38B	1.30B	710.88M
	Total Debt
107.10M	290.00K	401.00K	691.00K	20.86M	107.55M
	Net Debt
85.67M	-94.91M	-157.32M	-30.76M	-68.33M	84.06M
	Total Liabilities
199.33M	531.88M	362.36M	214.21M	177.50M	235.17M
	Stockholders Equity
447.82M	1.39B	1.32B	1.17B	1.12B	475.71M
Cash Flow		Free Cash Flow
-50.22M	-138.30M	-18.54M	-49.76M	-19.66M	45.53M
	Operating Cash Flow
244.42M	146.32M	249.86M	92.59M	97.16M	114.63M
	Investing Cash Flow
-229.44M	-148.88M	-170.81M	-63.17M	-469.13M	-69.31M
	Financing Cash Flow
-60.84M	-61.26M	48.69M	-86.93M	437.58M	-42.66M

Bachem Holding AG Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 53.05
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BANB, the sentiment is Neutral. The current price of 53.05 is above the 20-day moving average (MA) of 49.27, above the 50-day MA of 50.64, and below the 200-day MA of 62.56, indicating a neutral trend. The MACD of 0.65 indicates Negative momentum. The RSI at 64.82 is Neutral, neither overbought nor oversold. The STOCH value of 97.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:BANB.

Bachem Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BANB	70 Outperform	CHF3.96B	32.96	8.87%	1.52%	4.84%	7.45%
PPGN	54 Neutral	CHF665.58M	―		―	3.15%	62.88%
Sector *	52 Neutral	$5.14B	3.39	-43.55%	2.83%	16.49%	-0.19%

Bachem Holding AG Corporate Events

Bachem’s AGM 2025 Approves Board Proposals and Dividend

Bachem Holding AG announced that its Annual General Meeting 2025 approved all proposals from the Board of Directors, including a dividend of CHF 0.85 per share, to be paid on May 7, 2025. The meeting also saw the re-election of the President and Board members, the election of Dr. Simone Wyss Fedele to the Board, and the approval of various financial and sustainability reports. Forvis Mazars SA was appointed as the auditor for 2025. This approval reflects strong shareholder support and positions Bachem for continued stability and growth in the pharmaceutical and biotech sectors.

Bachem Proposes New Board Member with Extensive Life Sciences Experience

Bachem Holding AG announced the proposal of Dr. Simone Wyss Fedele, CEO of Switzerland Global Enterprise, for election as a new member of its Board of Directors at the upcoming General Meeting in April 2025. Dr. Fedele brings extensive experience in the life sciences industry and international trade, having held leadership roles at Novartis and Takeda Pharmaceuticals. Her addition is expected to enhance Bachem’s strategic positioning and strengthen its board with her international expertise and connections.